Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089709 | 0.82 | GABRA2 (0.42) | GABRA2GABRB2ARDPP4HRH4 | |
| SCHEMBL22030529 | 0.78 | GABRA2 (0.37) | GABRA2GABRB2CYP1A2CYP2C19DPP4 | |
| SCHEMBL18812323 | 0.78 | GABRA2 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL23979222 | 0.77 | GABRA2 (0.36) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL18367678 | 0.76 | KDM4E (0.36) | GABRA2GABRB2CYP1A2CYP2C19DPP4 | |
| SCHEMBL22380834 | 0.75 | GABRA2 (0.35) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL18077443 | 0.75 | GABRA2 (0.35) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL18367556 | 0.75 | GABRA2 (0.39) | GABRA2GABRB2ARDPP4HRH4 | |
| SCHEMBL18623676 | 0.74 | AR (0.49) | GABRA2GABRB2ARCYP1A2CYP2C19 | |
| SCHEMBL21135745 | 0.74 | DPP4 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | GABRA2 1471/4885GABRB2 1542/4885AR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.